{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:17:24Z","timestamp":1789049844231,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd015266","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000}}],"reference-count":128,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015266.pub2","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:16:08Z","timestamp":1772064968000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-6703","authenticated-orcid":false,"given":"Zhaolun","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of General Surgery; West China Hospital, Sichuan University; Chengdu China"},{"name":"Gastric Cancer Center; West China Hospital, Sichuan University; Chengdu China"},{"name":"Laboratory of Gastrointestinal Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-Related Molecular Network; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Meng","sequence":"additional","affiliation":[{"name":"Laboratory of Gastrointestinal Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-Related Molecular Network; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Urology; West China Second University Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Han","sequence":"additional","affiliation":[{"name":"Department of General Surgery; West China Hospital, Sichuan University; Chengdu China"},{"name":"Gastric Cancer Center; West China Hospital, Sichuan University; Chengdu China"},{"name":"Laboratory of Gastrointestinal Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-Related Molecular Network; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-5843","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery; West China Hospital, Sichuan University; Chengdu China"},{"name":"Gastric Cancer Center; West China Hospital, Sichuan University; Chengdu China"},{"name":"Laboratory of Gastrointestinal Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-Related Molecular Network; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0002|cit2","unstructured":"Cancer Research UK Bowel cancer incidence statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bowel-cancer\/incidence#heading-Zero (accessed 5 November 2025)"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0003|cit3","unstructured":"American Cancer Society Key Statistics for Colorectal Cancer https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/about\/key-statistics.html (accessed 20 April 2025)"},{"issue":"8","key":"10.1002\/14651858.CD015266.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"djw322","DOI":"10.1093\/jnci\/djw322","article-title":"Colorectal cancer incidence patterns in the United States, 1974-2013","volume":"109","author":"Siegel","year":"2017","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2019.11.029","article-title":"Use of family history and genetic testing to determine risk of colorectal cancer","volume":"158","author":"Kastrinos","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1002\/14651858.CD015266.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/cncr.30080","article-title":"Understanding the contribution of family history to colorectal cancer risk and its clinical implications: a state-of-the-science review","volume":"122","author":"Lowery","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2014.229","article-title":"Clinical management of hereditary colorectal cancer syndromes","volume":"12","author":"Vasen","year":"2015","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD015266.pub2-BIB0009|cit9","first-page":"784","article-title":"Colorectal cancer screening for patients with a family history of colorectal cancer or adenomas","volume":"65","author":"Wilkinson","year":"2019","journal-title":"Canadian Family Physician"},{"issue":"4","key":"10.1002\/14651858.CD015266.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"e239556","DOI":"10.1001\/jamanetworkopen.2023.9556","article-title":"Association of overweight, obesity, and recent weight loss with colorectal cancer risk","volume":"6","author":"Mandic","year":"2023","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1002\/14651858.CD015266.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.14309\/ajg.0000000000001393","article-title":"Association of body mass index with risk of early-onset colorectal cancer: systematic review and meta-analysis","volume":"116","author":"Li","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1136\/gutjnl-2021-325021","article-title":"Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites","volume":"71","author":"Bai","year":"2022","journal-title":"Gut"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.14309\/ajg.0000000000000803","article-title":"Smoking and colorectal cancer risk, overall and by molecular subtypes: a meta-analysis","volume":"115","author":"Botteri","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1038\/s41467-021-24861-8","article-title":"An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites","volume":"12","author":"Papadimitriou","year":"2021","journal-title":"Nature Communications"},{"issue":"9","key":"10.1002\/14651858.CD015266.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/ijc.31198","article-title":"Food groups and risk of colorectal cancer","volume":"142","author":"Schwingshackl","year":"2018","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD015266.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1093\/annonc\/mdx171","article-title":"Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR continuous update project","volume":"28","author":"Vieira","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"e2023092","DOI":"10.4178\/epih.e2023092","article-title":"Cancer risk based on alcohol consumption levels: a comprehensive systematic review and meta-analysis","volume":"45","author":"Jun","year":"2023","journal-title":"Epidemiology and Health"},{"issue":"10207","key":"10.1002\/14651858.CD015266.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015266.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/jnci\/93.10.743","article-title":"Chemoprevention: what\u2019s in a name?","volume":"93","author":"Theisen","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"issue":"10","key":"10.1002\/14651858.CD015266.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41416-022-01882-8","article-title":"Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies","volume":"127","author":"Zaman","year":"2022","journal-title":"British Journal of Cancer"},{"issue":"3A","key":"10.1002\/14651858.CD015266.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/s0002-9343(97)00203-9","article-title":"Mechanism of action of nonsteroidal anti-inflammatory drugs","volume":"104","author":"Vane","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015266.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ph3072146","article-title":"Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risks","volume":"3","author":"Meek","year":"2010","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004079.pub2","article-title":"Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas","author":"Asano","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0024|cit24","unstructured":"Cancer Council Australia Clinical practice guidelines for the prevention, early detection and management of colorectal cancer; 2023 Available from https:\/\/app.magicapp.org\/#\/guideline\/noPKwE"},{"issue":"7","key":"10.1002\/14651858.CD015266.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cgh.2021.02.014","article-title":"AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review","volume":"19","author":"Liang","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"16","key":"10.1002\/14651858.CD015266.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/apt.15333","article-title":"Population-based case-control study: chemoprotection of colorectal cancer with non-aspirin nonsteroidal anti-inflammatory drugs and other drugs for pain control","volume":"50","author":"Rodr\u00edguez-Miguel","year":"2019","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0029|cit29","unstructured":"FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes; July 2015 Available at https:\/\/www.fda.gov\/media\/92768\/download"},{"issue":"7553","key":"10.1002\/14651858.CD015266.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD015266.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/jnci\/djab008","article-title":"Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis","volume":"113","author":"Figueiredo","year":"2021","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nature Reviews Cancer"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1002\/14651858.CD015266.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cell.2019.01.016","article-title":"Acetylation blocks cgas activity and inhibits self-DNA-induced autoimmunity","volume":"176","author":"Dai","year":"2019","journal-title":"Cell"},{"issue":"16","key":"10.1002\/14651858.CD015266.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.7150\/thno.24284","article-title":"Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer","volume":"8","author":"Chen","year":"2018","journal-title":"Theranostics"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"e00547","DOI":"10.1128\/mBio.00547-21","article-title":"Aspirin modulation of the colorectal cancer-associated microbe Fusobacterium nucleatum","volume":"12","author":"Brennan","year":"2021","journal-title":"MBio"},{"issue":"10","key":"10.1002\/14651858.CD015266.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1-2","key":"10.1002\/14651858.CD015266.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mrrev.2008.03.002","article-title":"Inflammation: gearing the journey to cancer","volume":"659","author":"Kundu","year":"2008","journal-title":"Mutation Research"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","article-title":"COX-2: a molecular target for colorectal cancer prevention","volume":"23","author":"Brown","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.pharmtox.42.082301.164620","article-title":"COX-2: a target for colon cancer prevention","volume":"42","author":"Marnett","year":"2002","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0042|cit42","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2016.07.030","article-title":"Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes","volume":"151","author":"Cao","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD015266.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"issue":"10152","key":"10.1002\/14651858.CD015266.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/s0140-6736(18)31924-x","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0046|cit46","unstructured":"The ARRIVE study (aspirin to reduce risk of initial vascular events) - a randomized, double-blind, placebo controlled, multicenter, parallel group study to assess the efficacy (reduction of cardiovascular disease events) and safety of 100 mg enteric-coate https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-003622-29\/results"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0047|cit47","unstructured":"A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients at moderate risk of cardiovascular disease (ARRIVE) https:\/\/clinicaltrials.gov\/study\/NCT00501059"},{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults","volume":"113","author":"Mcneil","year":"2021","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0049|cit49","unstructured":"Aspirin in reducing events in the elderly (ASPREE) https:\/\/clinicaltrials.gov\/study\/NCT01038583"},{"issue":"6","key":"10.1002\/14651858.CD015266.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(20)30826-X","article-title":"337 major gastrointestinal bleeding in older persons using aspirin: incidence and risk factors in the aspree randomized controlled trial","volume":"158","author":"Mahady","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015266.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"S633","DOI":"10.1093\/geroni\/igz038.2358","article-title":"Effect of initiating aspirin on cancer events in the healthy elderly: primary results from the aspree randomized controlled trial","volume":"3","author":"Chan","year":"2019","journal-title":"Innovation in Aging"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"106095","DOI":"10.1016\/j.cct.2020.106095","article-title":"Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial","volume":"96","author":"Orchard","year":"2020","journal-title":"Contemporary Clinical Trials"},{"issue":"Supplement_1","key":"10.1002\/14651858.CD015266.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"dyab168.516","DOI":"10.1093\/ije\/dyab168.516","article-title":"Prevalence of cancer history and association with risk factors in a healthy older population","volume":"50","author":"Orchard","year":"2021","journal-title":"International Journal of Epidemiology"},{"issue":"16","key":"10.1002\/14651858.CD015266.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD015266.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9573","key":"10.1002\/14651858.CD015266.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/s0140-6736(07)60747-8","article-title":"Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies","volume":"369","author":"Flossmann","year":"2007","journal-title":"Lancet"},{"issue":"9754","key":"10.1002\/14651858.CD015266.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"6618","key":"10.1002\/14651858.CD015266.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"8","key":"10.1002\/14651858.CD015266.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2337\/dc18-0368","article-title":"Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial","volume":"41","author":"Okada","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0060|cit60","unstructured":"Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial https:\/\/clinicaltrials.gov\/study\/NCT00110448"},{"issue":"18","key":"10.1002\/14651858.CD015266.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/rth2.12097","article-title":"Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese","volume":"2","author":"Yokoyama","year":"2018","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0063|cit63","unstructured":"Japanese primary prevention project with aspirin https:\/\/clinicaltrials.gov\/study\/NCT00225849"},{"issue":"23","key":"10.1002\/14651858.CD015266.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"10.1002\/14651858.CD015266.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.V126.23.2322.2322","article-title":"Effects of daily aspirin on cancer incidence and mortality in the Japanese","volume":"126","author":"Yokoyama","year":"2015","journal-title":"Blood"},{"issue":"8779","key":"10.1002\/14651858.CD015266.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","article-title":"Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group","volume":"338","author":"The Salt Collaborative Group","year":"1991","journal-title":"Lancet"},{"issue":"9098","key":"10.1002\/14651858.CD015266.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results","volume":"54","author":"Farrell","year":"1991","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"suppl_11","key":"10.1002\/14651858.CD015266.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1093\/aje\/kws258","article-title":"Latent effects of low-dose aspirin on cancer: further follow-up of the women's health study","volume":"175","author":"Cook","year":"2012","journal-title":"American Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/heartjnl-2014-306342","article-title":"Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women","volume":"101","author":"Van Kruijsdijk","year":"2015","journal-title":"Heart (British Cardiac Society)"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.294.1.56","article-title":"Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial","volume":"294","author":"Lee","year":"2005","journal-title":"JAMA"},{"issue":"13","key":"10.1002\/14651858.CD015266.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0075|cit75","unstructured":"Women's health study (WHS): a randomized trial of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer (WHS) https:\/\/clinicaltrials.gov\/study\/NCT00000479"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.clon.2015.11.008","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"28","author":"Paleari","year":"2016","journal-title":"Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD015266.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1001\/jama.2013.6599","article-title":"Aspirin use and risk of colorectal cancer according to BRAF mutation status","volume":"309","author":"Nishihara","year":"2013","journal-title":"JAMA"},{"issue":"233","key":"10.1002\/14651858.CD015266.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"233re2","DOI":"10.1126\/scitranslmed.3008481","article-title":"Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD)","volume":"6","author":"Fink","year":"2014","journal-title":"Science Translational Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015266.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jama.2015.1815","article-title":"Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants","volume":"313","author":"Nan","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0080|cit80","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.4.2025 Available from https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"16","key":"10.1002\/14651858.CD015266.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.2022.3337","article-title":"Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"327","author":"Guirguis-Blake","year":"2022","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0083|cit83","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London. Version August 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/mecir-manual"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015266","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin for preventing colorectal adenomas and cancers in the general population","author":"Cai","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0086|cit86","unstructured":"Safety reporting requirements for INDs and BA\/BE studies; December 2012 https:\/\/www.fda.gov\/media\/79394\/download"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0087|cit87","unstructured":"International Council for Harmonisation Integrated addedum to ICH E6(R1): guideline for good clinical practice E6(R2) https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0088|cit88","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (last updated March 2025). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1. Cochrane, 2025 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","author":"Glanville","year":"2019","journal-title":"Health Information and Libraries Journal"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0090|cit90","unstructured":"Covidence Veritas Health Innovation 2025"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0091|cit91","unstructured":"Engauge Digitizer Mitchell M 2020 10.5281\/zenodo.3941227"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0092|cit92","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0095|cit95","unstructured":"Eldridge S Campbell M Campbell M Drahota-Towns A Giraudeau B Reeves B Revised Cochrane risk of bias toolfor randomized trials (RoB 2). Additional considerations for cluster-randomized trials (RoB 2 CRT); March 2021 Available at https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/rob-2-for-cluster-randomized-trials"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0096|cit96","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0097|cit97","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch23"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0099|cit99","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch12"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0102|cit102","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2025"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0103|cit103","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0104|cit104","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD015266.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"713","DOI":"10.7326\/0003-4819-128-9-199805010-00003","article-title":"Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study","volume":"128","author":"St\u00fcrmer","year":"1998","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0107|cit107","first-page":"S10","article-title":"Risk for colorectal cancer (CRC) after initiation of regular nonsteroidal antiinflammatory drug (NSAID) use: post trial follow up data from the physicians' health study (PHS)","volume":"159","author":"St\u00fcrmer","year":"2004","journal-title":"American Journal of Epidemiology"},{"issue":"15","key":"10.1002\/14651858.CD015266.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/jnci\/85.15.1220","article-title":"Low-dose aspirin and incidence of colorectal tumors in a randomized trial","volume":"85","author":"Gann","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD015266.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.amjmed.2005.11.011","article-title":"Colorectal cancer after start of nonsteroidal anti-inflammatory drug use","volume":"119","author":"St\u00fcrmer","year":"2006","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing physicians' health study","volume":"321","author":"Steering Committee of the Physicians' Health Study Research Group","year":"1989","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0111|cit111","first-page":"411a","article-title":"Low-dose aspirin and risk of developing colorectal polyps: the Physicians' Health Study","volume":"16","author":"Lee","year":"1997","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0112|cit112","doi-asserted-by":"crossref","unstructured":"Wolfe R Broder J Chan A Murray A Orchard S Polekhina G Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial medRxiv 2023 10.1101\/2023.09.13.23295514","DOI":"10.1101\/2023.09.13.23295514"},{"issue":"4","key":"10.1002\/14651858.CD015266.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1053\/j.gastro.2012.08.017","article-title":"Aspirin and chemoprevention of cancer: reaching beyond the colon","volume":"143","author":"Chan","year":"2012","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1002\/14651858.CD015266.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/jco.23.01680","article-title":"Improved survival with adjuvant cyclooxygenase 2 inhibition in pik3ca-activated stage III colon cancer: CALGB\/SWOG 80702 (alliance)","volume":"42","author":"Nowak","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015266.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/ede.0000000000000471","article-title":"The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine","volume":"27","author":"Ogino","year":"2016","journal-title":"Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-pathmechdis-012418-012818","article-title":"Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology","volume":"14","author":"Ogino","year":"2019","journal-title":"Annual Review of Pathology"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13063-022-06132-z","article-title":"Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease","volume":"23","author":"Gallagher","year":"2022","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0118|cit118","unstructured":"Aspirin to target arterial events in chronic kidney disease (ATTACK) https:\/\/clinicaltrials.gov\/show\/NCT03796156"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jclinepi.2021.04.014","article-title":"Corrigendum to GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"137","author":"Guyatt","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD015266.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"116","DOI":"10.69854\/jcq.2024.0016","article-title":"Minimal clinically important difference (MCID) of effect sizes other than mean difference","volume":"1","author":"Horita","year":"2024","journal-title":"Journal of Clinical Question"},{"issue":"5","key":"10.1002\/14651858.CD015266.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","article-title":"Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019","volume":"31","author":"Bosetti","year":"2020","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD015266.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00384-021-03880-3","article-title":"Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"36","author":"Ghaddaf","year":"2021","journal-title":"International Journal of Colorectal Disease"},{"issue":"1","key":"10.1002\/14651858.CD015266.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12885-020-07117-4","article-title":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1002\/14651858.CD015266.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00384-021-03889-8","article-title":"Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials","volume":"36","author":"Ma","year":"2021","journal-title":"International Journal of Colorectal Disease"},{"issue":"7","key":"10.1002\/14651858.CD015266.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/cm9.0000000000002514","article-title":"Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis","volume":"136","author":"Ma","year":"2023","journal-title":"Chinese Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD015266.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/bjs\/znad231","article-title":"Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses","volume":"110","author":"Shah","year":"2023","journal-title":"British Journal of Surgery"},{"key":"10.1002\/14651858.CD015266.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"690219","DOI":"10.3389\/fonc.2021.690219","article-title":"Aspirin use and common cancer risk: a meta-analysis of cohort studies and randomized controlled trials","volume":"11","author":"Wang","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015266.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/pubmed\/fdz114","article-title":"Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies","volume":"43","author":"Wang","year":"2021","journal-title":"Journal of Public Health"}],"updated-by":[{"DOI":"10.1002\/14651858.cd015266.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:01:24Z","timestamp":1772449284000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015266.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":128,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015266.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}